A Respiratory Syncytial Virus vaccine based on the Small Hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study.
about
A Respiratory Syncytial Virus vaccine based on the Small Hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
A Respiratory Syncytial Virus ...... ults: a first-in-humans study.
@en
A Respiratory Syncytial Virus ...... ults: a first-in-humans study.
@nl
type
label
A Respiratory Syncytial Virus ...... ults: a first-in-humans study.
@en
A Respiratory Syncytial Virus ...... ults: a first-in-humans study.
@nl
prefLabel
A Respiratory Syncytial Virus ...... ults: a first-in-humans study.
@en
A Respiratory Syncytial Virus ...... ults: a first-in-humans study.
@nl
P2093
P2860
P50
P356
P1476
A Respiratory Syncytial Virus ...... ults: a first-in-humans study.
@en
P2093
Bert Schepens
Genevieve M Weir
Lingyun Ye
Lisa D MacDonald
Marianne M Stanford
Xavier Saelens
P2860
P356
10.1093/INFDIS/JIY177
P407
P577
2018-03-30T00:00:00Z